Swapnil Hiremath profile picture

Contact Information

Swapnil Hiremath, MD, MPH, FASN
6137388400 x 82762
shiremath@toh.ca

ORCID ID: 0000-0003-0010-3416



ORCID logo https://orcid.org/0000-0003-0010-3416

Funding

FUNDING SUMMARY
• 18 grants, total funding: $4,239,634
• As nominated principal applicant or principal applicant: $854,766
• External Agencies (CIHR/Kidney Foundation of Canada/AHRQ/PSI): $3,010,554

FUNDING DETAILS

18. Predicting renal recovery in patients re-quiring outpatient dialysis after acute kid-ney injury (RECOVER AKI) Ontario Renal Net-work Co-investigator
[PI: Edward Clark] July 2018 to June 2019, C$147,230
17. Diet or Additional Supplement to Increase Potassium Intake: An Adaptive Clinical Trial Hecht Foundation Nominated Principal Applicant July 2018 to June 2021; C$286,540
16. Saline versus albumin fluid for extracor-poreal removal with slow low efficiency dialysis. Department of Medicine, University of Ottawa Principal Investi-gator
[nominated PI: Edward Clark] July 2017 to June 2019; C$47,988
15. Blood Pressure Measurement: Should technique Define Targets? Physician Services Incorporated Principal Investi-gator [nominated PI Marcel Ruzicka] August 2017 to July 2018; C$45,000
14. What is the Evidence Behind the Rec-ommendation of Withholding Certain Medications before Contrast Procedures? A Systematic review of the Evidence Canadian Institute of Health Research Nominated Prin-cipal Applicant July 2016 to June 2017
C$ 99,000
13. The ACCESS trial: A Randomized trial comparing Catheters to Fistula in Elderly Patients starting Dialysis Canadian Institute of Health Research co-Investigator [PI: Dr Rob Quinn, Calgary] Sep 2015 - Feb 2018
C$ 513,898
12. Standard versus Accelerated Initaition of Renal Replacement Therapy (STARRT-AKI) Canadian Institute of Health Research co-Investigator [PI: Dr Ron Wald, Toronto] Sep 2015 - Aug 2019
C$1,608,548
11. Protein Supplementation for Thiazide-diuretic induced hyponatremia: A Pilot Study’ The Ottawa Hospital Academic Medical Organization Principal Investi-gator [nominated PI Marcel Ruzicka] July 2015 to June 2018
C$89,998
10. Assessment of Effectiveness of Counselling by a Registered Dietician on Low Salt Diet in Patients with Hypertension: A Pragmatic Clinical Trial The Ottawa Hospital Academic Medical Organization Principal Investi-gator [nominated PI Marcel Ruzicka] July 2014 to June 2017
C$95,055
9. The Prevention of Acute Kidney Injury after Contrast-Enhanced Computed To-mography: A Pilot trial of Oral Fluid ver-sus Intravenous Saline Department of Medi-cine, University of Ottawa (internal fund-ing, competitive, peer-reviewed) Principal Investi-gator July 2013 to June 2016
C$114,775
8. Antimicrobial pharmacokinetics in critical-ly ill adults during sustained low efficiency dialysis Kidney Foundation of Canada co-Investigator [PI: Dr Salmaan Kanji] July 2014 - June 2016
C$100,000
7. Standard versus Accelerated Initaition of Renal Replacement Therapy (STARRT-AKI): Pilot Trial Canadian Institute of Health Research co-Investigator [PI: Dr Ron Wald, Toronto] Sep 2014 - Aug 2019
C$220,996
6. Reducing the Risk of serious adverse events and improving quality of life for patients with kidney disease: the role of arteriovenous fistula creation in dialysis Canadian Institute of Health Research co-Investigator [PI: Dr Rob Quinn, Calgary] March 2013 - Feb 2015
C$152,879
5. Curcumin to Prevent Peri-operative Complications after Elective Abdominal Aortic Aneurysm Repair. Canadian Institute of Health Research co-Investigator [PI: Dr Amit Garg, London] Oct 2010 - Oct 2014
C$328,530]
4. E-health Interventions to Improve Vascu-lar Health in Workplaces: Foundational Research Examining Physical Activity Among Nurses Working in Hospitals University of Ottawa Heart Institute co-Investigator [PI: Dr Bob Reid] May 2014 - May 2015
C$ 50,000
3. Troponin Cardiac Marker Interpretation During Renal Function Impairment Agency for Healthcare Research and Quality co-Investigator [PI: Mohammed Ansari] 2009
$162,699
2. Centre for Excellence for Treatment of Resistant Hypertension: Establishment and Critical Evaluation of Efficacy, Mechanisms and Safety of Renal Sympa-thetic Denervation The Ottawa Hospital Academic Medical Organization co-Investigator [PI: Dr Ruzicka] July 2014 - June 2017
C$99,998
1. Cost-Effectiveness of Visipaque in pa-tients with Renal Insufficiency. GE Healthcare (In-dustry) co-PI [PI Ben Chow, Heart In-stitute] June 2012- June 2015;
C$ 76,500